Menu
News
Recent news
Santersus AG today announced the successful completion of its Series A financing, led by Norcliffe, a UK life sciences fund with participation from Terumo Ventures. The financing will support the advancement of Santersus’ NucleoCapture™ into pivotal clinical development while accelerating progress across Santersus’ broader pipeline.
December 11, 2025
Santersus AG today announced two senior leadership appointments that strengthen the company’s executive and governance capabilities as it advances its NucleoCapture™ toward pivotal clinical development.
August 27, 2025
Santersus AG today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its NucleoCapture™ blood purification technology for the treatment of severe, treatment-refractory systemic lupus erythematosus (SLE). This marks the second Breakthrough Device Designation awarded to NucleoCapture™, following earlier recognition for the treatment of sepsis.
Santersus AG congratulates its alliance partner OrganOx Ltd on the company’s acquisition by Terumo Corporation in a transaction valued at up to $1.5 billion — a major milestone in the evolution of global transplant technologies.